Abstract:BACKGROUND:The oncolytic Newcastle disease virus (NDV) is inherently able to trigger the lysis of tumor cells and induce the immunogenic cell death (ICD) of tumor cells and is also an excellent gene-engineering vector. The macrophage inflammatory protein-3α (MIP-3α) is a specific chemokine for dendritic cells (DCs). Thus, we constructed a recombinant NDV expressing MIP-3α (NDV-MIP3α) as an in vivo DC vaccine for amplifying antitumor immunities.METHODS:The recombinant NDV-MIP3α was constructed by the insertion of MIP-3α cDNA between the P and M genes. Western blotting assay and ELISA were used to detect MIP-3α, HMGB1, IgG, and ATP in the supernatant and sera. The chemotaxis of DCs was examined by Transwell chambers. The phenotypes of the immune cells (eg, DCs) were analyzed by flow cytometry. The antitumor efficiency of NDV-MIP3α was observed in B16 and CT26 tumor-bearing mice. Immunofluorescence and immunohistochemistry were applied to observe the ecto-calreticulin (CRT) and intratumoral attraction of DCs. Adoptive transfer of splenocytes and antibodies and depletion of T-cell subsets were used to evaluate the relationship between antitumor immunities and the role of the T-cell subtype.RESULTS:The findings show that NDV-MIP3α has almost the same capabilities of tumor lysis and induction of ICD as the wild-type NDV (NDV-WT). MIP-3α secreted by NDV-MIP3α could successfully attract DCs in vitro and in vivo. Both B16 and CT26 cells infected with NDV-MIP3α could strongly promote DC maturation and activation. Compared with NDV-WT, intratumoral injection of NDV-MIP3α and the adoptive transfer of T lymphocytes from mice injected with NDV-MIP3α resulted in a significant suppression of B16 and CT26 tumor growth. The NDV-MIP3α-induced production of tumor-specific cellular and humoral immune responses was dependent on CD8+ T cells and partially on CD4+ T cells. A significant reversion of tumor microenvironments was found in the mice injected with NDV-MIP3α.CONCLUSIONS:Compared with NDV-WT, the recombinant NDV-MIP3α as an in vivo DC vaccine demonstrates enhanced antitumor activities through the induction of stronger system immunities and modulation of the tumor microenvironment. This strategy may be a potential approach for the generation of an in vivo DC vaccine.

Genetically Engineered Newcastle Disease Virus Expressing Interleukin-2 and TNF-related Apoptosis-Inducing Ligand for Cancer Therapy.

TNF-related Apoptosis-inducing Ligand Delivered by Rndv is a Novel Agent for Cancer Gene Therapy

Recombinant Newcastle Disease Virus (Ndv/anh-Il-2) Expressing Human IL-2 As a Potential Candidate for Suppresses Growth of Hepatoma Therapy.

Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting

Use of Reverse Genetics to Enhance the Oncolytic Properties of Newcastle Disease Virus

Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model

Expressing Foreign Genes by Newcastle Disease Virus for Cancer Therapy

Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy

Construction of Recombinant Newcastle Disease Virus Italien Strain for Oncolytic Virotherapy of Tumors.

Newcastle disease virus: A promising agent for tumour immunotherapy

Selective Gene Transfer to Tumor Cells by Recombinant Newcastle Disease Virus Via a Bispecific Fusion Protein

Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer

Recombinant Newcastle Disease Virus Anhinga Strain and TRAIL Protein Cooperate to Kill Cancer Cells in Culture

In Vivo Efficacy of Systemic Tumor Targeting of a Viral RNA Vector with Oncolytic Properties Using a Bispecific Adapter Protein.

Selective Gene Transfer in Vitro to Tumor Cells Via Recombinant Newcastle Disease Virus

Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model

A Recombinant Oncolytic Newcastle Virus Expressing MIP-3α Promotes Systemic Antitumor Immunity.